The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease

Gastroenterology

Volumn 140, Issue 6, 2011, Pages 1817-1826.e2

  Lewis, James D ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 720 Blockley Hall ^*  (United States)

Author keywords

Biomarker; Crohn's Disease; Prognosis; Ulcerative Colitis

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; DRUG METABOLITE; FUNGUS ANTIBODY; INFLIXIMAB; LACTOFERRIN; MERCAPTOPURINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROTEIN 100A12; PYRUVATE KINASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL FEATURE; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; SACCHAROMYCES CEREVISIAE; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 79955555545     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.11.058     Document Type: Article

References (112)

1. J. Langhorst, S. Elsenbruch, and T. Mueller Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis Inflamm Bowel Dis 11 2005 1085 1091 (Pubitemid 41682565)
2. O. Saitoh, K. Kojima, and K. Sugi Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease (comment) Am J Gastroenterol 94 1999 3513 3520
3. K. Sugi, O. Saitoh, and I. Hirata Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins Am J Gastroenterol 91 1996 927 934 (Pubitemid 26143531)
4. A. Poullis, R. Foster, and T.C. Northfield Review article: faecal markers in the assessment of activity in inflammatory bowel disease Aliment Pharmacol Ther 16 2002 675 681 (Pubitemid 34407514)
5. I. Angriman, M. Scarpa, and R. D'Inca Enzymes in feces: useful markers of chronic inflammatory bowel disease Clin Chim Acta 381 2007 63 68 (Pubitemid 46719135)
6. K. Becker, C. Niederau, and T. Frieling Fecal excretion of α 2-macroglobulin: a novel marker for disease activity in patients with inflammatory bowel disease Z Gastroenterol 37 1999 597 605 (Pubitemid 29378863)
7. F. Casellas, M. Antolin, and E. Varela Fecal excretion of human deoxyribonucleic acid as an index of inflammatory activity in ulcerative colitis Clin Gastroenterol Hepatol 2 2004 683 689 (Pubitemid 39013428)
8. G. Chung-Faye, B.H. Hayee, and S. Maestranzi Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation Inflamm Bowel Dis 13 2007 1374 1378 (Pubitemid 350206848)
9. E. Czub, K.-H. Herzig, and A. Szaflarska-Popawska Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease Scand J Gastroenterol 42 2007 1147 1150 (Pubitemid 47537095)
10. N.S.H. de Jong, S.T. Leach, and A.S. Day Fecal S100A12: a novel noninvasive marker in children with Crohn's disease Inflamm Bowel Dis 12 2006 566 572 (Pubitemid 43977737)
11. M. Hocke, L. Richter, and H. Bosseckert Platelet activating factor in stool from patients with ulcerative colitis and Crohn's disease Hepatogastroenterology 46 1999 2333 2337 (Pubitemid 29454094)
12. J. Jansson, B. Willing, and M. Lucio Metabolomics reveals metabolic biomarkers of Crohn's disease (Electronic resource) PLoS One 4 2009 e6386
13. J. Jeffery, S.J. Lewis, and R.M. Ayling Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders Inflamm Bowel Dis 15 2009 1630 1634
14. J.O. Lundberg, P.M. Hellstrom, and M.K. Fagerhol Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease Nat Clin Pract Gastroenterol Hepatol 2 2005 96 102 (Pubitemid 40790156)
15. I. Masoodi, R. Kochhar, and U. Dutta Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis J Gastroenterol Hepatol 24 2009 1768 1774
16. O.H. Nielsen, P. Gionchetti, and M. Ainsworth Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-α in ulcerative colitis Am J Gastroenterol 94 1999 2923 2928 (Pubitemid 29482759)
17. C.G.B. Peterson, P. Sangfelt, and M. Wagner Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis Scand J Clin Lab Invest 67 2007 810 820 (Pubitemid 350158774)
18. M. Wagner, C.G.B. Peterson, and P. Ridefelt Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease World J Gastroenterol 14 2008 5584 5589
19. S. Vermeire, G. Van Assche, and P. Rutgeerts Laboratory markers in IBD: useful, magic, or unnecessary toys Gut 55 2006 436431
20. A.G. Roseth, M.K. Fagerhol, and E. Aadland Assessment of the neutrophil dominating protein calprotectin in feces A methodologic study Scand J Gastroenterol 27 1992 793 798
21. J. Tibble, K. Teahon, and B. Thjodleifsson A simple method for assessing intestinal inflammation in Crohn's disease Gut 47 2000 506 513
22. A.C. von Roon, L. Karamountzos, and S. Purkayastha Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy Am J Gastroenterol 102 2007 803 813 (Pubitemid 46496634)
23. P.F. van Rheenen, E. Van de Vijver, and V. Fidler Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis BMJ 341 2010 c3369
24. S.V. Kane, W.J. Sandborn, and P.A. Rufo Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation Am J Gastroenterol 98 2003 1309 1314 (Pubitemid 36741528)
25. J.P. Gisbert, A.G. McNicholl, and F. Gomollon Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease Inflamm Bowel Dis 15 2009 1746 1754
26. M. Joishy, I. Davies, and M. Ahmed Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease J Pediatr Gastroenterol Nutr 48 2009 48 54
27. J. Langhorst, S. Elsenbruch, and J. Koelzer Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices Am J Gastroenterol 103 2008 162 169
28. H. Silberer, B. Kuppers, and O. Mickisch Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome Clin Lab 51 2005 117 126 (Pubitemid 40520584)
29. T. Kaiser, J. Langhorst, and H. Wittkowski Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome Gut 56 2007 1706 1713 (Pubitemid 350206297)
30. A.C. Manolakis, A.N. Kapsoritakis, and P. Georgoulias Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome BMC Gastroenterol 10 2010 118
31. R.M. Beattie, J.A. Walker-Smith, and S.H. Murch Indications for investigation of chronic gastrointestinal symptoms Arch Dis Child 73 1995 354 355
32. A.P. Poullis, S. Zar, and K.K. Sundaram A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders Eur J Gastroenterol Hepatol 14 2002 409 412 (Pubitemid 34439041)
33. B. Shine, L. Berghouse, and J.E. Jones C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders Clin Chim Acta 148 1985 105 109 (Pubitemid 15034646)
34. J.D. Lewis C-reactive protein: anti-placebo or predictor of response Gastroenterology 129 2005 1114 1116 (Pubitemid 41242700)
35. F.M. Ruemmele, S.R. Targan, and G. Levy Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease Gastroenterology 115 1998 822 829 (Pubitemid 28452928)
36. G.E. Reese, V.A. Constantinides, and C. Simillis Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease Am J Gastroenterol 101 2006 2410 2422 (Pubitemid 44477569)
37. S. Benor, G.H. Russell, and M. Silver Shortcomings of the inflammatory bowel disease serology 7 panel Pediatrics 125 2010 1230 1236
38. N. Sabery, and D. Bass Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia Pediatrics 119 2007 e193 e199
39. H. McKenzie, J. Main, and C.R. Pennington Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease Gut 31 1990 536 538 (Pubitemid 20185955)
40. A. Standaert-Vitse, T. Jouault, and P. Vandewalle Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease Gastroenterology 130 2006 1764 1775 (Pubitemid 43668842)
41. I. Dotan, S. Fishman, and Y. Dgani Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease Gastroenterology 131 2006 366 378 (Pubitemid 44142445)
42. D. Simondi, G. Mengozzi, and S. Betteto Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease Inflamm Bowel Dis 14 2008 645 651 (Pubitemid 351742981)
43. M. Ferrante, L. Henckaerts, and M. Joossens New serological markers in inflammatory bowel disease are associated with complicated disease behaviour Gut 56 2007 1394 1403 (Pubitemid 47517833)
44. S. Joossens, W. Reinisch, and S. Vermeire The value of serologic markers in indeterminate colitis: a prospective follow-up study Gastroenterology 122 2002 1242 1247 (Pubitemid 34465166)
45. S. Joossens, J.F. Colombel, and C. Landers Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis Gut 55 2006 1667 1669 (Pubitemid 44629225)
46. P. Vandewalle-El Khoury, J.F. Colombel, and S. Joossens Detection of antisynthetic mannoside antibodies (AΣMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and prediction Am J Gastroenterol 103 2008 949 957 (Pubitemid 351501080)
47. A.G. Roseth, E. Aadland, and J. Jahnsen Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein Digestion 58 1997 176 180 (Pubitemid 27163169)
48. A.G. Roseth, E. Aadland, and K. Grzyb Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease Scand J Gastroenterol 39 2004 1017 1020 (Pubitemid 39388470)
49. T. Sipponen, E. Savilahti, and K.L. Kolho Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings Inflamm Bowel Dis 14 2008 40 46 (Pubitemid 351196867)
50. R. D'Inca, E. Dal Pont, and V. Di Leo Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease Int J Colorectal Dis 22 2007 429 437 (Pubitemid 46336248)
51. H. Hanai, K. Takeuchi, and T. Iida Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis Dig Dis Sci 49 2004 1438 1443 (Pubitemid 39273619)
52. T. Sipponen, P. Karkkainen, and E. Savilahti Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings Aliment Pharmacol Ther 28 2008 1221 1229
53. U.L. Fagerberg, L. Loof, and J. Lindholm Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease J Pediatr Gastroenterol Nutr 45 2007 414 420 (Pubitemid 350307158)
54. J. Jones, E.V. Loftus Jr, and R. Panaccione Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease Clin Gastroenterol Hepatol 6 2008 1218 1224
55. T. Sipponen, E. Savilahti, and P. Karkkainen Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-α therapy for Crohn's disease Inflamm Bowel Dis 14 2008 1392 1398
56. A.M. Schoepfer, C. Beglinger, and A. Straumann Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI Am J Gastroenterol 105 2010 162 169
57. A.M. Schoepfer, C. Beglinger, and A. Straumann Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes Inflamm Bowel Dis 15 2009 1851 1858
58. T. Sipponen, E. Savilahti, and K.-L. Kolho Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings Inflamm Bowel Dis 14 2008 40 46 (Pubitemid 351196867)
59. T. Sipponen, C.-G.A.F. Bjorkesten, and M. Farkkila Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment Scand J Gastroenterol 45 2010 325 331
60. C.A. Solem, E.V. Loftus Jr, and W.J. Tremaine Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease Inflamm Bowel Dis 11 2005 707 712 (Pubitemid 41271173)
61. E.A. Fagan, R.F. Dyck, and P.N. Maton Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis Eur J Clin Invest 12 1982 351 359 (Pubitemid 12024511)
62. B. Cakal, A.G. Akoz, and Y. Ustundag Red cell distribution width for assessment of activity of inflammatory bowel disease Dig Dis Sci 54 2009 842 847
63. A.D. Rodgers, and A.G. Cummins CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease Dig Dis Sci 52 2007 2063 2068 (Pubitemid 47246515)
64. K.F. Froslie, J. Jahnsen, and B.A. Moum Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort Gastroenterology 133 2007 412 422 (Pubitemid 47187355)
65. F. Baert, L. Moortgat, and G. Van Assche Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease Gastroenterology 138 2010 463 468 quiz e10e11
66. P. Rutgeerts, K. Geboes, and G. Vantrappen Predictability of the postoperative course of Crohn's disease Gastroenterology 99 1990 956 963 (Pubitemid 20338451)
67. M. Scarpa, R. D'Inca, and D. Basso Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease Dis Colon Rectum 50 2007 861 869 (Pubitemid 46870452)
68. C.A. Lamb, M.K. Mohiuddin, and J. Gicquel Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease Br J Surg 96 2009 663 674
69. A. Orlando, I. Modesto, and F. Castiglione The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound Eur Rev Med Pharmacol Sci 10 2006 17 22
70. M.J. Romberg-Camps, P.C. Dagnelie, and A.D. Kester Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease Am J Gastroenterol 104 2009 371 383
71. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology.
72. N. Gupta, S.A. Cohen, and A.G. Bostrom Risk factors for initial surgery in pediatric patients with Crohn's disease Gastroenterology 130 2006 1069 1077
73. P. Munkholm, E. Langholz, and M. Davidsen Intestinal cancer risk and mortality in patients with Crohn's disease Gastroenterology 105 1993 1716 1723 (Pubitemid 24002788)
74. W.S. Mow, E.A. Vasiliauskas, and Y.-C. Lin Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease Gastroenterology 126 2004 414 424 (Pubitemid 38182298)
75. S.R. Targan, C.J. Landers, and H. Yang Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease Gastroenterology 128 2005 2020 2028 (Pubitemid 40824710)
76. D.K. Amre, S.E. Lu, and F. Costea Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients Am J Gastroenterol 101 2006 645 652 (Pubitemid 43340944)
77. M.C. Dubinsky, Y.C. Lin, and D. Dutridge Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression Am J Gastroenterol 101 2006 360 367 (Pubitemid 43381681)
78. M.C. Dubinsky, S. Kugathasan, and L. Mei Increased immune reactivity predicts aggressive complicating Crohn's disease in children Clin Gastroenterol Hepatol 6 2008 1105 1111
79. F. Costa, M.G. Mumolo, and L. Ceccarelli Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease (comment) Gut 54 2005 364 368 (Pubitemid 40299092)
80. J.A. Tibble, G. Sigthorsson, and S. Bridger Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease (comment) Gastroenterology 119 2000 15 22 (Pubitemid 30452574)
81. J.P. Gisbert, F. Bermejo, and J.-L. Perez-Calle Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse Inflamm Bowel Dis 15 2009 1190 1198
82. R. D'Inca, E. Dal Pont, and V. Di Leo Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 103 2008 2007 2014
83. T. Sipponen, and K.L. Kolho Faecal calprotectin in children with clinically quiescent inflammatory bowel disease Scand J Gastroenterol 45 2010 872 877
84. D. Walkiewicz, S.L. Werlin, and D. Fish Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease Inflamm Bowel Dis 14 2008 669 673 (Pubitemid 351742984)
85. Y. Consigny, R. Modigliani, and J.F. Colombel A simple biological score for predicting low risk of short-term relapse in Crohn's disease Inflamm Bowel Dis 12 2006 551 557 (Pubitemid 43977735)
86. M. Boirivant, M. Leoni, and D. Tariciotti The clinical significance of serum C reactive protein levels in Crohn's disease Results of a prospective longitudinal study J Clin Gastroenterol 10 1988 401 405
87. C. Brignola, M. Campieri, and G. Bazzocchi A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease Gastroenterology 91 1986 1490 1494 (Pubitemid 17176866)
88. Oussalah A, Chevaux JB, Fay R, et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol 105:1142-1149.
89. A. Bitton, P.L. Dobkin, and M.D. Edwardes Predicting relapse in Crohn's disease: a biopsychosocial model Gut 57 2008 1386 1392
90. C. Papi, V. Festa, and G. Leandro Long-term outcome of Crohn's disease following corticosteroid-induced remission Am J Gastroenterol 102 2007 814 819 (Pubitemid 46496609)
91. A. Bitton, M.A. Peppercorn, and D.A. Antonioli Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis Gastroenterology 120 2001 13 20 (Pubitemid 32061864)
92. G.T. Ho, H.M. Lee, and G. Brydon Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis Am J Gastroenterol 104 2009 673 678
93. S.P. Travis, J.M. Farrant, and C. Ricketts Predicting outcome in severe ulcerative colitis Gut 38 1996 905 910 (Pubitemid 26231777)
94. D. Turner, D. Mack, and N. Leleiko Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response Gastroenterology 138 2010 2282 2291
95. D. Turner, S.T. Leach, and D. Mack Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response Gut 59 2010 1207 1212
96. K.D. Taylor, S.E. Plevy, and H. Yang ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease Gastroenterology 120 2001 1347 1355 (Pubitemid 32322308)
97. N. Esters, S. Vermeire, and S. Joossens Serological markers for prediction of response to antitumor necrosis factor treatment in Crohn's disease Am J Gastroenterol 97 2002 1458 1462 (Pubitemid 34664792)
98. M. Ferrante, S. Vermeire, and K.H. Katsanos Predictors of early response to infliximab in patients with ulcerative colitis Inflamm Bowel Dis 13 2007 123 128 (Pubitemid 46806219)
99. M.C. Dubinsky, L. Mei, and M. Friedman Genome wide association (GWA) predictors of anti-TNFα therapeutic responsiveness in pediatric inflammatory bowel disease Inflamm Bowel Dis 16 2010 1357 1366
100. J. Spivak, C.J. Landers, and E.A. Vasiliauskas Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease Inflamm Bowel Dis 12 2006 1122 1130 (Pubitemid 44847469)
101. M. Osterman, R. Kundu, and G. Lichtenstein Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis Gastroenterology 130 2006 1047 1053
102. T. Dassopoulos, C. Martin, and J. Galanko A randomized trial of metabolite-adjusted versus weight-based dosing of azathioprine (AZA) in Crohn's disease (CD) Gastronterology 136 2009 A-519
103. M.L. Haines, Y. Ajlouni, and P.M. Irving Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease Inflamm Bowel Dis 2010
104. A.K. Waljee, J.C. Joyce, and S. Wang Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines Clin Gastroenterol Hepatol 8 2010 143 150
105. F. Baert, M. Noman, and S. Vermeire Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease (comment) N Engl J Med 348 2003 601 608 (Pubitemid 36204954)
106. E.A. Maser, R. Villela, and M.S. Silverberg Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease Clin Gastroenterol Hepatol 4 2006 1248 1254 (Pubitemid 44512213)
107. J.F. Colombel, W.J. Sandborn, and W. Reinisch Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
108. K. Karmiris, G. Paintaud, and M. Noman Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease Gastroenterology 137 2009 1628 1640
109. C.H. Seow, A. Newman, and S.P. Irwin Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis Gut 59 2010 49 54
110. W. Afif, E.V. Loftus Jr, and W.A. Faubion Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease Am J Gastroenterol 105 2010 1133 1139
111. S.H. Saverymuttu, M. Camilleri, and H. Rees Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion Gastroenterology 90 1986 1121 1128 (Pubitemid 16145475)
112. P.G. Farup, O. Hovde, and F.A. Halvorsen Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis A comparison of the efficacy and practicality of two topical treatment regimens Scand J Gastroenterol 30 1995 164 170